The pleiotropic actions of neuromodulators on pre-and postsynaptic targets make disentangling the mechanisms underlying regulation of synaptic transmission challenging. In the striatum, acetylcholine modulates glutamate release via activation of muscarinic receptors (mAchRs), although the consequences for postsynaptic signaling are unclear. Using two-photon microscopy and glutamate uncaging to examine individual synapses in the rat striatum, we found that glutamatergic afferents have a high degree of multivesicular release (MVR) in the absence of postsynaptic receptor saturation. We found that mAchR activation decreased both the probability of release and the concentration of glutamate in the synaptic cleft. The corresponding decrease in synaptic potency reduced the duration of synaptic potentials and limited temporal summation of afferent inputs. These findings reveal a mechanism by which a combination of basal MVR and low receptor saturation allow the presynaptic actions of a neuromodulator to control the engagement of postsynaptic nonlinearities and regulate synaptic integration.
The pleiotropic actions of neuromodulators on pre-and postsynaptic targets make disentangling the mechanisms underlying regulation of synaptic transmission challenging. In the striatum, acetylcholine modulates glutamate release via activation of muscarinic receptors (mAchRs), although the consequences for postsynaptic signaling are unclear. Using two-photon microscopy and glutamate uncaging to examine individual synapses in the rat striatum, we found that glutamatergic afferents have a high degree of multivesicular release (MVR) in the absence of postsynaptic receptor saturation. We found that mAchR activation decreased both the probability of release and the concentration of glutamate in the synaptic cleft. The corresponding decrease in synaptic potency reduced the duration of synaptic potentials and limited temporal summation of afferent inputs. These findings reveal a mechanism by which a combination of basal MVR and low receptor saturation allow the presynaptic actions of a neuromodulator to control the engagement of postsynaptic nonlinearities and regulate synaptic integration.
Neuromodulatory systems in the mammalian brain regulate behavioral state, circuit plasticity and synaptic transmission 1 . Perturbations of neuromodulators such as acetylcholine (Ach), dopamine and serotonin contribute to the pathogenesis and treatment of neuropsychiatric disorders including Parkinson's disease, schizophrenia and major depression [2] [3] [4] [5] . In contrast with classical neurotransmitters that directly excite or inhibit postsynaptic neurons, neuromodulators generally alter the biochemical state of the neuron, influencing the activities of receptors, ion channels and signaling cascades. These pleiotropic effects present major technical challenges to the elucidation of the specific mechanisms underlying neuromodulation of brain function. This difficulty is evident in the striatum, an important component of the basal ganglia that is necessary for the proper generation of movement and that is regulated by neuromodulators such as dopamine and Ach [6] [7] [8] . Ach is released in the striatum by interneurons, and disruption of cholinergic signaling impairs both movement and learning of operant conditioning tasks 9, 10 . Moreover, perturbation of striatal cholinergic signaling contributes to movement disorders that include Huntington's and Parkinson's diseases 4, 11, 12 .
The majority of cells in the striatum are medium spiny neurons (MSNs) that receive glutamatergic inputs from the cortex and thalamus 13, 14 . Presynaptic terminals of these afferents express M2-type mAchRs, whose activation reduces the magnitude of synaptic responses in the striatum [15] [16] [17] [18] [19] . MSNs express both M1-and M4-type mAchRs, and ultrastructural analysis has shown that cholinergic terminals are typically apposed to dendritic shafts and spine necks, suggesting that cholinergic receptors may also regulate postsynaptic properties [20] [21] [22] . Previous studies found minimal effects of mAchR activation on postsynaptic glutamatergic currents 16, 23 (but see ref. 24 ). Nevertheless, mAchR activation modulates the intrinsic membrane properties of MSNs, reducing currents through various voltage-gated Ca 2+ and K + channels [25] [26] [27] [28] . As nonlinear interactions between voltage-sensitive glutamate receptors and other channels can influence synaptic response magnitude and integration 29, 30 , muscarinic actions on glutamatergic signaling remain unclear.
We studied the modulation of excitatory synapses onto MSNs, combining two-photon laser-scanning microscopy (2PLSM) and two-photon laser uncaging of glutamate (2PLU) to determine the pre-and postsynaptic actions of mAchRs. Optical quantal analysis revealed that mAchR activation reduced both the probability of glutamate release from the presynaptic terminal and the potency of individual synapses. However, mAchR activation did not directly modulate glutamate receptors. Our results indicate that striatal glutamatergic synapses exhibit a high basal rate of MVR without substantial saturation of glutamate receptors. We found that synaptic potency regulated the duration and temporal summation of excitatory postsynaptic potentials. Thus, the combination of basal MVR, lack of receptor saturation and dendritic nonlinearities allows presynaptic neuromodulation to control both synaptic potency and temporal integration in MSNs.
RESULTS
We measured the effects of mAchR activation on glutamatergic postsynaptic responses in the striatum. In whole-cell current-clamp recordings, paired-pulse electrical stimulation (50-ms interval) evoked depressing excitatory postsynaptic potentials (EPSPs; Fig. 1a ). Application of muscarine, a general mAchR agonist, reduced the amplitudes of evoked responses, depolarized the resting membrane potential (V m ; Fig. 1a -c) and increased the paired-pulse ratio (PPR). On average (n ¼ 7), muscarine reduced the first EPSP from 8.1 ± 1.6 mV to 4.8 ± 0.8 mV (P o 0.05) and the second EPSP from 6.5 ± 1.4 mV to 4.9 ± 0.8 mV (P o 0.05), increasing the PPR from 0.9 ± 0.1 to 1.2 ± 0.1 (P o 0.05) (Fig. 1d) . The average V m depolarized from À73.6 ± 0.8 mV to À67.8 ± 1.6 mV (P o 0.05; Fig. 1d ), without change in the input resistance (data not shown). In whole-cell voltage-clamp recordings (V hold ¼ À75 mV), muscarine reduced the amplitudes of excitatory postsynaptic currents (EPSCs) and increased the PPR (Fig. 1e ). On average (n ¼ 6), muscarine reduced the first EPSC from 131.8 ± 27.5 pA to 86.7 ± 19.3 pA (P o 0.05) and the second EPSC from 111.7 ± 26.2 pA to 89.9 ± 20.7 pA (P o 0.05), increasing the PPR from 0.8 ± 0.1 to 1.1 ± 0.1 (P o 0.05; Fig. 1f ). These data indicate that mAchR activation exerts both presynaptic (alterations in PPR) and postsynaptic (depolarization) actions in addition to producing effects of unclear origin (reduction of synaptic responses).
Optical quantal analysis of glutamatergic synapses
To determine the effects of mAchR activation at individual synapses, we measured the probability of vesicular release and the synaptic potency (the average response magnitude when release occurs from the presynaptic terminal 31, 32 ) with optical quantal analysis. 2PLSM was used to place a stimulating electrode B10 mm from spiny regions of the proximal dendrite ( Fig. 2a) . Electrode position and stimulus strength were adjusted until a single spine in the field of view was activated, as judged by a Ca 2+ -dependent increase in green fluorescence limited to a single spine head ( Fig. 2b) . Recordings were made in the presence of the AMPA receptor (AMPAR) antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (NBQX) and the cell was voltage-clamped at 0-10 mV (the empirically determined reversal potential for NMDA receptors, NMDARs) to eliminate net synaptically evoked current and prevent changes in potential in the active spine. By collecting evoked fluorescence changes in the spine and neighboring dendrite, success and failure trials could be distinguished ( Fig. 2c ). Under these conditions, synaptic Ca 2+ influx occurred through NMDARs and was blocked by the NMDAR antagonist D(À)-2-amino-5-phosphonovaleric acid (AP5; Fig. 2d ).
The probability of success of glutamate release (P s ) was determined as the fraction of trials that evoked a fluorescence transient in the spine head. Synaptic potency (Pot NMDA ) was measured as the average amplitude of fluorescence transients in the spine head (DG/R) in successful trials. In a separate set of experiments, we monitored P s and Pot NMDA in individual spines during application of muscarine ( Fig. 3a) . Muscarine increased the fraction of failure trials and decreased DG/R on success trials with no effect on resting fluorescence (Fig. 3b ). On average (n ¼ 10), muscarine decreased P s from 0.91 ± 0.04 to 0.74 ± 0.05 (P o 0.05) and Pot NMDA from 34.3 ± 6.1% to 18.4 ± 3.2% (P o 0.05; Fig. 3c ).
Uncaging-evoked synaptic currents and Ca 2+ transients
To determine whether mAchRs directly regulate postsynaptic glutamate receptors, we examined responses evoked by 2PLU. MSNs were voltage-clamped at À70 mV in the presence of tetrodotoxin (TTX) and voltage-gated calcium channel (VGCC) blockers (see Online Methods). To stimulate each spine with a consistent amount of glutamate, we adjusted the laser power such that a 500-ms pulse directed at the spine head bleached B50% of the red fluorescence ( Fig. 4a-c) 33 . After setting laser power, the periphery of the spine was probed to find the uncaging position that evoked the largest uncaging-evoked EPSC (uEPSC) 34 . In the presence of the NMDAR antagonist (RS)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP), uncaging evoked brief inward currents ( Fig. 4d ) with amplitudes similar to those of miniature EPSCs 35 . On average (n ¼ 26), the non-NMDARmediated uEPSC was 17.2 ± 1.6 pA ( Fig. 4e) and was not significantly altered in the presence of muscarine (17.4 ± 2.4 pA, n ¼ 24, P 4 0.05), indicating that mAchR activation does not modulate postsynaptic AMPAR currents.
We performed a similar analysis in the presence of the AMPAR antagonist NBQX and in nominally 0 mM extracellular Mg 2+ . In these conditions, at a holding potential of À70 mV, 2PLU evoked NMDARmediated uEPSCs and Ca 2+ influx into the spine ( Fig. 5a-d) . Neither NMDAR-mediated currents nor Ca influx under control conditions (5.0 ± 0.7 pA, DG/R ¼ 46.0 ± 6.1%, n ¼ 15) were significantly different from those that occurred in the presence of muscarine (4.3 ± 0.6 pA, DG/R ¼ 49.2 ± 6.3%, n ¼ 15, P 4 0.05; Fig. 5e ). When we repeated these experiments under the voltage-clamp conditions that we used for optical quantal analysis (0-10 mV), there was negligible NMDAR-mediated current flow and muscarine again had no effect on NMDAR-mediated Ca 2+ transients (n ¼ 19, DG/R ¼ 195.4 ± 19.2% versus 200.7 ± 27.4% for control and muscarine, respectively; Fig. 5f ). Thus, although activation of mAchRs regulates NMDAR-mediated synaptic potency, it does not directly modulate the opening probability or Ca 2+ permeability of NMDARs. 
Presynaptic control of synaptic potency
Our data indicate that mAchR activation alters synaptic potency without any direct modulation of glutamate receptors. Such effects could arise if synapses exhibit MVR and mAchR activation reduces the number of released vesicles. In this case, other manipulations of presynaptic release probability should also alter potency. We therefore examined the effects of the N-type VGCC blocker o-Conotoxin GVIA (1.0 mM, Ctx), which is known to reduce the release probability at these synapses 15 , using optical quantal analysis ( Fig. 6a ). Similar to muscarine application, Ctx increased the fraction of synaptic failures and reduced the amplitude of Ca 2+ transients on success trials ( Fig. 6b ). On average (n ¼ 5), Ctx application reduced P s from 0.55 ± 0.12 to 0.30 ± 0.11 (P o 0.05) and Pot NMDA from 87.4 ± 8.2% to 57.8 ± 9.2% (P o 0.05, Fig. 6c ). Measurement of 2PLU-evoked Ca 2+ transients in neurons clamped at 0-10 mV confirmed a lack of postsynaptic effect of Ctx on NMDAR-mediated Ca 2+ transients ( Fig. 6d) .
To further test whether decreased presynaptic release probability could account for the reduction in synaptic potency, we calculated the relative change in Pot NMDA expected for a change in P s using a Poisson model of vesicular release (see Online Methods). The observed reductions in Pot NMDA for the muscarine and Ctx experiments were well predicted by the decreases in P s , yielding an average residual error of 19.4% (Fig. 6e) . In total, our results indicate that direct manipulation of presynaptic release probability alters synaptic potency in the striatum, which is consistent with a high degree of MVR under basal conditions being reduced by muscarine or Ctx application. 
Glutamate receptors are not saturated in basal conditions
For postsynaptic receptors to follow changes in the concentration of synaptically released glutamate, AMPARs and NMDARs must not be fully saturated. To examine the degree of receptor saturation, we used 2PLU to stimulate spines with different levels of glutamate. Experiments were performed in the presence of TTX and VGCC antagonists, and laser power was determined as described above (1Â condition). Evoked currents were then measured using nominally 0.5Â, 1Â and 2Â laser power (as a result of non-uniform intensity during the 500-ms laser pulse, the actual range of power modulation was less than fourfold). In the presence of NBQX and no extracellular Mg 2+ (n ¼ 13), these three stimuli resulted in NMDAR-mediated uEPSCs of 6.4 ± 1.2 pA, 13.0 ± 2.6 pA and 21.6 ± 4.1 pA, respectively, and Ca 2+ transients of 58.3 ± 10.6%, 90.1 ± 10.6% and 111.3 ± 10.5%, respectively (Fig. 7a) . Similar experiments in the presence of CPP (n ¼ 11) resulted in non-NMDAR-mediated uEPSCs of 12.5 ± 3.1 pA, 21.1 ± 5.7 pA and 30.3 ± 7.0 pA, respectively (Fig. 7b) . The currents and Ca 2+ transients evoked by the 0.5Â and 2.0Â conditions were significantly different from the 1Â condition-evoked responses (P o 0.05; Fig. 7c,d) .
To further study the possibility of receptor saturation, we examined the effect of the low-affinity competitive AMPAR antagonist g-D-glutamylglycine (g-DGG) on electrically evoked EPSCs. If receptors are substantially saturated by synaptic activation, decreasing glutamate release by reducing extracellular Ca 2+ should enhance the current block by g-DGG. We recorded AMPAR-mediated EPSCs following paired-pulse stimulation in the presence of CPP. Application of g-DGG in control artificial cerebrospinal fluid (ACSF, 2 mM Ca 2+ ) reduced the amplitudes of the first and second EPSCs and increased PPR (Fig. 7e) . The increase in PPR is consistent with the relief by g-DGG of AMPAR desensitization during paired-pulse activation 29 . On average (n ¼ 13), g-DGG significantly reduced the first EPSC to 35.7 ± 2.9% of the control (P o 0.05) and increased PPR from 0.77 ± 0.04 to 1.0 ± 0.06 (P o 0.05; Fig. 7f ). Reducing the extracellular Ca 2+ concentration to 1 mM significantly increased PPR (P o 0.05; Fig. 7f ), indicating a reduction in presynaptic release probability. In 1 mM Ca 2+ , on average (n ¼ 7), g-DGG reduced the first EPSC to 43.5 ± 5.6% of the control (P o 0.05) and increased PPR from 0.97 ± 0.06 to 1.31 ± 0.05 (P o 0.05; Fig. 7f ). The reduction of EPSC amplitude by g-DGG did not differ between control and low Ca 2+ conditions, consistent with there being little AMPAR saturation.
Synaptic potency regulates temporal integration
MSNs exhibit voltage-dependent nonlinearities, such as interactions between VGCCs and NMDARs, that enhance the magnitude and summation of synaptic responses 29, 30 . We theorized that changes in synaptic potency should influence depolarization in active spines and potentially regulate postsynaptic integration. We therefore re-examined modulation of electrically evoked EPSPs in cells in which the somatic V m was held constant (Fig. 8a) . At hyperpolarized potentials (V m ¼ À85 mV), muscarine decreased the EPSP amplitude from 9.5 ± 0.9 mV to 5.0 ± 0.7 mV (n ¼ 6, P o 0.05), but did not significantly alter the EPSP width (19.2 ± 1.5 ms versus 18.5 ± 0.9 ms for control and muscarine, respectively; P 4 0.05, Fig. 8b ). In cells held at À70 mV, muscarine decreased the average EPSP amplitude from 8.5 ± 0.8 mV to 5.6 ± 1.0 (n ¼ 6, P o 0.05) and reduced the EPSP width from 32.3 ± 2.3 ms to 25.2 ± 2.5 ms (P o 0.05; Fig. 8b) . These results suggest that changes in synaptic potency can alter response kinetics by influencing postsynaptic voltage-dependent nonlinearities, although this effect may be absent at hyperpolarized potentials as a result of mAchR-mediated closure of inwardly rectifying potassium channels 28 .
To further explore this hypothesis, we mimicked a reduction in synaptic potency by co-applying low concentrations of NBQX and CPP. These agents decrease the strength of activation of individual synapses without confounding alteration of postsynaptic membrane properties. We determined the concentration of NBQX and CPP necessary to reduce AMPAR and NMDAR currents, respectively, by B40-50% (the potency decrease seen using optical quantal analysis). In the presence of CPP, application of 0.1 mM NBQX reduced the amplitude of electrically evoked AMPAR-mediated EPSCs from 158.1 ± 12.2 to 91.8 ± 18.0 pA (n ¼ 6). In the presence of NBQX, application of 1.0 mM CPP reduced the amplitude of NMDAR-mediated EPSCs (holding potential ¼ 40 mV) from 184.6 ± 22.6 to 106.4 ± 26.9 pA (n ¼ 4). These antagonists had no significant effect on the width of either AMPARmediated (3.2 ± 0.2 versus 3.6 ± 0.3 ms, P 4 0.05) or NMDARmediated (83.6 ± 7.3 versus 81.0 ± 6.2 ms, P 4 0.05) EPSCs (control versus drug, respectively). We next compared EPSPs evoked in control conditions, following co-application of NBQX (0.1 mM) and CPP (1.0 mM), and after increasing stimulus strength in the presence of NBQX and CPP to restore the amplitude of the EPSP to that measured in control conditions (Fig. 8c) . This tests the hypothesis that changes in synaptic potency and changes in the total number of active synapses have qualitatively different effects on postsynaptic responses. Co-application of NBQX and CPP reduced the EPSP amplitude and width at halfmaximal amplitude (Fig. 8c) . Increasing stimulus intensity returned the amplitude to that seen in control conditions, but did not restore the EPSP width. On average (n ¼ 8), decreasing synaptic potency reduced the EPSP amplitude from 11.9 ± 0.9 to 6.6 ± 1.2 mV (P o 0.05) and the EPSP width from 31.1 ± 4.2 to 22.3 ± 2.8 ms (P o 0.05; Fig. 8d ). Increasing the total number of active synapses by increasing stimulus intensity restored the EPSP amplitude (12.4 ± 0.9 mV), but failed to restore the EPSP width (21.9 ± 2.2 ms, P o 0.05 relative to control), indicating that this parameter is selectively sensitive to the single synapse potency and not to the cumulative multisynaptic depolarization.
The narrowing of the EPSP following reduction in synaptic potency was sufficient to affect the temporal summation of synaptic potentials during paired simulation (Fig. 8e ). On average (n ¼ 7), under control conditions, the amplitude of the second EPSP relative to that of the first EPSP at 50-ms and 20-ms intervals was 1.16 ± 0.04 and 1.39 ± 0.08, respectively (Fig. 8f) . Following co-application of NBQX and CPP and an offsetting increase in stimulation strength, the relative amplitudes of the second EPSPs at the two intervals were significantly reduced to 0.99 ± 0.04 (P o 0.05) and 1.12 ± 0.13 (P o 0.05), respectively. These results demonstrate that modulation of synaptic potency regulates integration independently of changes in the total postsynaptic depolarization.
DISCUSSION
Ach contributes to the regulation of brain function through a diversity of actions 5, [36] [37] [38] . In the striatum, Ach is released by interneurons that receive inputs from the cortex and thalamus, providing feedforward modulation that is critical for the generation of normal movement and learning in operant conditioning tasks 4, [9] [10] [11] . We used optical methods to analyze the pre-and postsynaptic effects of mAchR activation. As described previously, we found that Ach acts presynaptically to reduce the probability of glutamate release at excitatory synapses [15] [16] [17] 19 . We also found that striatal glutamatergic synapses showed a high basal degree of MVR and that cholinergic reduction of release probability decreased the potency of individual synapses by lowering the concentration of glutamate in the synaptic cleft. Decreasing synaptic potency reduced the duration of postsynaptic EPSPs and limited their temporal summation. Our results provide a detailed description of cholinergic actions at a single central synapse and demonstrate a previously unknown mechanism of presynaptic control over postsynaptic integration.
Presynaptic regulation of synaptic potency
Presynaptic terminals of striatal afferent fibers express M2-type mAchRs, the activation of which reduces evoked and spontaneous synaptic responses and increases PPRs (Fig. 1 and refs. 15-17,19,23) . Thus, mAchR activation decreases the release probability, most likely via inhibition of presynaptic P/Q-type VGCCs 15 iontophoretically applied glutamate 16 or the amplitude of spontaneous synaptic events 23 , although one study found that muscarinic agonists enhanced the response to exogenously applied NMDA 24 . However, activation of postsynaptic M1-type mAchRs inhibits N-and L-type VGCCs, as well as multiple potassium conductances [25] [26] [27] [28] 39, 40 , and these effects may indirectly modulate glutamate transmission as a result of the voltage dependence of NMDAR opening. Indeed, L-type VGCCs and NMDARs can interact to boost and broaden postsynaptic responses in MSNs 29, 30 .
Our results indicate that muscarine reduces synaptic potency by decreasing the concentration of released glutamate in the synaptic cleft. We conclude that the most likely explanation is that striatal glutamatergic boutons release multiple vesicles per action potential under basal conditions. Application of muscarine reduces the probability of release, thereby decreasing the number of fusion events and, consequently, the synaptic glutamate concentration. This conclusion is dependent on two assumptions. First, that the Ca 2+ transient observed in each spine is mediated by glutamate release from a single presynaptic terminal, a position supported by ultrastructural analysis showing that most MSN spines are targeted by a single glutamatergic bouton 13, 14 . Second, spillover of glutamate from neighboring synapses does not contribute to measured spine Ca 2+ transients. In support of this assumption, spine Ca 2+ imaging is sensitive to the opening of single NMDARs 41 , and local electrical stimulation in analyzed experiments did not result in measurable Ca 2+ transients in neighboring spines. In addition, the VGCC blocker Ctx acutely mimicked the actions of muscarine, arguing strongly that changes in glutamate clearance or vesicle filling are unlikely to explain our results.
Multivesicular release has been observed at a variety of central synapses. Cerebellar parallel fiber-Purkinje cell 42 and hippocampal CA3-CA1 synapses exhibit low basal release probability 31, 43, 44 , but MVR can occur when release is enhanced. In contrast, at retinal bipolar cells to amacrine AII ribbon synapses 45 and climbing fiber inputs to Purkinje cells 46, 47 , the probability of release and occurrence of MVR is high under basal conditions. Similarly, we found that striatal glutamatergic synapses have a high release probability and a pronounced degree of MVR during basal transmission. The functional consequences of MVR depend on the degree of receptor saturation, which limits the postsynaptic sensitivity to varying glutamate concentration. Using either glutamate uncaging or application of the low-affinity AMPAR antagonist g-DGG, we found that neither AMPARs nor NMDARs at striatal glutamatergic synapses were saturated, despite the occurrence of MVR.
Functional consequences
The activity of individual MSNs in vivo is dependent on the integration of synchronous synaptic inputs arriving predominantly from the cortex 48 . Furthermore, integration in MSNs is inherently nonlinear as a result of engagement of dendritic voltage-dependent conductances and dependence on the spatiotemporal pattern of active synapses 29 . We found that activation of mAchRs narrowed EPSPs. Moreover, mimicking reduced potency with glutamate receptor antagonists also shortened EPSP duration and decreased temporal summation. This effect was not a result of a reduction in the total number of active synapses. One possible explanation is that reduced glutamate per synapse produces less depolarization in individual spines, thus decreasing the activation of voltage-sensitive channels, including L-type VGCCs and NMDARs 29, 30 .
Our findings differ from those of a previous study showing that mAchR activation increases the duration of EPSPs as a result of a reduction of an inwardly rectifying potassium conductance 28 .
However, this earlier study was performed at more hyperpolarized potentials and with NMDARs blocked, preventing the voltage-dependent boosting of EPSP amplitude and duration. Indeed, in our experiments, muscarine did not produce a narrowing of EPSPs recorded at -85 mV. Our results suggest that the release of Ach diminishes the ability of MSNs to respond to synchronized cortical inputs, particularly at relatively depolarized potentials seen in vivo. Furthermore, they suggest that other striatal modulators of presynaptic release probability, such as endocannabinoids 49 , are also likely to produce postsynaptic changes in EPSP kinetics and temporal integration. Finally, given the changes in release probability that occur across development, determining the contribution of MVR to synaptic transmission and neuromodulation in older animals remains an interesting avenue for future exploration.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureneuroscience/.
ONLINE METHODS
Slice preparation and pharmacology. All animal handling was performed in accordance with guidelines approved by the Harvard Institutional Animal Care and Use Committee and federal guidelines. Recordings were made from MSNs in striatal slices taken from postnatal day 15-18 Sprague-Dawley rats. Sagittal (Fig. 8) or coronal ( Figs. 1-7 ) slices (300 mm thick) were cut in ice-cold external solution containing 110 mM choline, 25 mM NaHCO 3 , 1.25 mM NaH 2 PO 4 , 2.5 mM KCl, 7 mM MgCl 2 , 0.5 mM CaCl 2 , 25 mM glucose, 11.6 mM sodium ascorbate and 3.1 mM sodium pyruvate, bubbled with 95% O 2 and 5% CO 2 . Slices were then transferred to ACSF containing 127 mM NaCl, 25 mM NaHCO 3 , 1.25 mM NaH 2 PO 4 , 2.5 mM KCl, 1 mM MgCl 2 , 2 mM CaCl 2 and 25 mM glucose, bubbled with 95% O 2 and 5% CO 2 . After an incubation period of 30-40 min at 34 1C, the slices were stored at 22-25 1C. All experiments were conducted at 32 1C. In all experiments, 50 mM picrotoxin was present in the ACSF to block GABA A/C receptor-mediated inhibition. For all glutamate uncaging experiments, 10 mM serine was included in the ACSF to reduce NMDAR desensitization and VGCCs were blocked with a cocktail of 1 mM o-conotoxin-MVIIC (N/P/Q types), 20 mM nimodipine (L types) and 10 mM mibefradil (R and T types). For some experiments, extracellular MgCl 2 was nominally reduced to 0 mM. In experiments in which extracellular Ca 2+ was reduced to 1 mM, Mg 2+ was increased to 2 mM to maintain a constant concentration of divalent ions. Finally, in some experiments, one or more of the following drugs were added to the ACSF, unless otherwise stated, at the following concentrations 10 mM muscarine, 10 mM NBQX, 10 mM CPP, 50 mM AP5, 1 mM TTX, 1 mM o-conotoxin-GVIA or 2500 mM g-DGG. To block B50% of AMPARs and NMDARs (Fig. 8) , 0.1 and 1 mM of NBQX and CPP were used, respectively. All chemicals were from Sigma or Tocris, with the exception of o-conotoxin-GVIA and o-conotoxin-MVIIC (Peptides International).
Electrophysiology and imaging. Whole-cell recordings were obtained from MSNs identified with infrared differential interference contrast videomicroscopy and 2PLSM on the basis of their small cell bodies and prominent dendritic spines. For current-clamp recordings, glass electrodes (2-4 MO) were filled with internal solution containing 135 mM KMeSO 3 , 10 mM HEPES, 4 mM MgCl 2 , 4 mM Na 2 ATP, 0.4 mM NaGTP and 10 mM sodium creatine phosphate, adjusted to pH 7.4 with KOH. For voltage-clamp recordings, cesium was substituted for potassium to improve space clamping. For physiology-only experiments, 1 mM EGTA and 20 mM Alexa Fluor-594 (to image neuronal morphology) were added to the internal solution. For Ca 2+ -imaging experiments, 300 mM of the Ca 2+ -sensitive indicator Fluo-5F and 20 mM Alexa Fluor-594 were added. Current and voltage recordings were made using a Multiclamp 700B amplifier. Data was filtered at 5 kHz and digitized at 10 kHz. Excitatory input fibers were stimulated with a small glass electrode (tip diameter, 2-4 mm) filled with ACSF using brief (0.2 ms) current injections. For paired-pulse stimulation experiments, the electrode was placed at the border between the striatum and the overlying white matter. For optical quantal analysis experiments, the electrode was placed B10 mm from the dendritic spine of interest.
Intracellular Ca 2+ imaging and glutamate uncaging were accomplished with a custom microscope combining 2PLSM and 2PLU, as previously described 33, 35 . Neurons were filled via the patch electrode for 10-15 min before imaging. Fluo-5F (green) and Alexa Fluor-594 (red) were excited using 840-nm light to monitor Ca 2+ signals and spine morphology, respectively. To measure Ca 2+ signals, we collected green and red fluorescence during 500-Hz line scans across a spine and a neighboring dendrite. Ca 2+ signals were quantified as increases in green fluorescence from baseline normalized to the red fluorescence (DG/R). Reference frame scans were taken between each acquisition to correct for small spatial drift of the preparation over time.
For 2PLU experiments, MNI-glutamate was bath applied at 2.5 mM, and glutamate uncaging was achieved using a 0.5-ms pulse of 720-nm light. To achieve standard uncaging power, (which translates into a constant amount of glutamate uncaged on each trial) we used photobleaching of Alexa Fluo-594 in the spine of interest as previously described 33 . Bleaching is a function of the laser power and thus provides readout of power delivery that is independent of spine depth and electrophysiological responses.
Data acquisition and analysis. Imaging and physiology data were acquired using National Instruments boards and custom software written in MATLAB (Mathworks) 50 . Off-line analysis was performed using custom routines written in MATLAB and Igor Pro (Wavemetrics). Peak amplitudes of electrically evoked EPSPs were calculated by averaging a 3-ms window around the peak. The amplitudes of electrically evoked EPSCs and uncaging-evoked EPSCs mediated by AMPARs were calculated by averaging over a 2-ms window, whereas a 10-ms window was used to calculate peaks of NMDAR-mediated EPSCs. EPSP and EPSC widths were calculated as the interval between points at half-maximal amplitude. For imaging experiments, measurements of DG/R were calculated by taking the average of the signal over a 150-ms poststimulus window.
For paired-pulse experiments, we measured the response to a single stimulation or paired stimulation at an interstimulus interval of 50 or 20 ms. The PPR was calculated by subtracting the response to the single stimulus from the response to the paired stimulus and then calculating the ratio of the peak of the remaining response to the single response.
For optical quantal analysis, successes were distinguished from failures by setting a threshold equal to two s.d. above baseline noise. To determine the effect of muscarine and Ctx on the amplitude of NMDAR-mediated Ca 2+ signals, we compared the average DG/R on success trials during the baseline period with the average DG/R after application of each drug. The probability of success was calculated by dividing the number of successful trials by the total number of trials during either baseline or after bath application of each drug. To ensure that the dendrite was not stimulated directly, we limited our analysis to those experiments in which Ca 2+ entry was confined to a single spine.
In sections describing optical or uncaging responses measured from individual spines, the stated n indicates the number of spines analyzed. In sections describing electrically evoked synaptic responses, the stated n indicates the number of cells analyzed. All statistics are expressed as mean ± s.e.m. and comparisons were made using a two-tailed Student's t test. Differences were judged to be statistically significant for P o 0.05.
Poisson model. To test whether reduced probability of vesicle release could adequately explain the observed changes in postsynaptic potency, we developed a Poisson model of synaptic transmission that assumes independent release of multiple docked vesicles per active zone. In this model, the probability of release of x vesicles following an action potential is given by a function of a single parameter l that is the average number of released vesicles (that is, l ¼ ox4), such that:
Therefore, the probability of release of one or more vesicles (that is, P s , the probability of seeing a synaptic response on any given trial) is related to l by l ¼ À ln ðPð0ÞÞ ¼ À ln ð1 À P s Þ Assuming a linear relationship between the number of released vesicles and the degree of NMDAR activation, the mean spine head Ca 2+ transient amplitude (averaged across all trials including successes and failures) is given by
where q is the quantal postsynaptic amplitude for a single vesicle. Furthermore, the mean spine head Ca 2+ transient amplitude of only success trials (the synaptic potency, Pot NMDA ) is
If the quantal amplitude q is the same in two conditions (that is, before and after drug application), the ratio of synaptic potencies in the two conditions is purely a function of the probability of successful vesicular release Figure 6e shows the results of using this equation to predict changes in synaptic potency for all experiments involving either muscarine or Ctx application. We plotted the expected fractional change in Pot NMDA as a function of the observed change in P s . The model ignores possible supralinearities in the activation of NMDARs as a result of a Hill coefficient of greater than 1 for activation by glutamate and possible sublinearities resulting from saturation of Ca 2+ indicator. Despite these simplifications and the lack of free parameters, Equation (1) fits the experimental data with a residual error of o20%.
